General Description Indication Usage and Dosage Side effects
ChemicalBook > CAS DataBase List > Esomeprazole


General Description Indication Usage and Dosage Side effects
Esomeprazole Structure
  • CAS No.119141-88-7
  • Chemical Name:Esomeprazole
  • CBNumber:CB6740618
  • Molecular Formula:C17H19N3O3S
  • Formula Weight:345.42
  • MOL File:119141-88-7.mol
Esomeprazole Property
  • alpha  :D20 -155° (c = 0.5 in chloroform)
  • Boiling point: :600.0±60.0 °C(Predicted)
  • Density  :1.37±0.1 g/cm3(Predicted)
  • pka :8.50±0.10(Predicted)
  • CAS DataBase Reference :119141-88-7(CAS DataBase Reference)
  • FDA UNII :N3PA6559FT
  • HS Code  :29339900
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal word
  • Hazard statements
  • Precautionary statements

Esomeprazole Chemical Properties,Usage,Production

  • General Description Esomeprazole (English brand name: Inexium), is the S-isomer of omeprazole. In 1990, in vitro gastric gland model confirmed that two isomers of omeprazole have the same proton pump inhibitory effect. However, it was not possible at that time to prepare a sufficient number of individual isomers for in vivo testing, and the isolated isomers could be slowly racemized in aqueous solution. When sufficient amounts of both isoforms were available for human tesing, the effect of the oral S-isomer was proved to be about 4 times better than that of the R-isomer. Esomeprazole decreases the amount of acid produced in the stomach through specific targeting. It is weakly alkaline and works as a specific inhibitor of proton pumps in parietal cells. Also it concentrates and transforms into an active form in the acid environment of the parietal oxynticus microtubules, thus inhibiting H / K-ATPase (proton pump) of this body part and inhibiting the the secretion of basic gastric acid and stimulated gastric acid. Its curative effects for gastroesophageal reflux disease are better than omeprazole in terms of symptoms relief, inhibition of gastric acid produced in the stomach and promoting the improvement of esophagitis.
  • Indication
    1. Gastroesophageal reflux disease (GERD) is when food or liquid travels from the stomach back up into the esophagus, often causing heartburn, acid reflux, retrosternal pain and other symptoms, and also causing pathologic damage to esophageal mucosa. GERD is one of the common clinical acid-related diseases, and the key to treat the gastroesophageal reflux disease is to inhibit gastric acid secretion. Esomeprazole (eaomeprazole) is the laevo isomer of omeprazole (Nexium), used to treat eflux esophagitis with quick effect and good acid suppression. It can be used alone or in combination with Prokinetic agent or gastrointestinal mucosal protective agent,and its curative effect is better than other PPI (esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole),Also it’s safe and effective for the elderly and children infected with reflux esophagitis.
    2. Erosive reflux esophagitis treatment
    3. Long-term maintenance for healed esophagitis patients.
    4. To control symptoms of gastroesophageal reflux disease (GERD) and combine with appropriate antimicrobial therapy to eradicate ofHelicobacter pylori
    5. To heal the Helicobacter pylori-related duodenal ulcer
    6. To prevent the Helicobacter pylori -related peptic ulcer recurrence.
  • Usage and Dosage Swallow the tablet together with the liquid. Don’t chew or crush.
    • Gastroesophageal Reflux Disease (GERD)
    1. Erosive reflux esophagitis treatment: 40mg once a day. 
    Duration of therapy: four weeks.
    2. An additional 4 weeks may be considered for patients with esophagitis not healed or the symptoms don’t resolve after initial treatment. Long-term maintenance for healed esophagitis patients: 20mg once a day.
    3. Gastroesophageal reflux disease (GERD) symptom control
    Patients without esophagitis: 20mg once a day. If symptoms are not controlled after 4 weeks, further examinations should be done to the patient. Once the symptoms have been resolved, 20 mg orally once a day should be taken to maintain the symptom resolution and healing.
    4. Combine with appropriate antibiotic therapy to eradicate Helicobacter pylori, heal the Helicobacter pylori-related duodenal ulcer and prevent the Helicobacter pylori -related peptic ulcer recurrence.  
    Triple therapy: esomeprazole 20 mg + amoxillin 1 g + clarithromycin 500mg, twice a day. Duration of therapy: 7 days.
  • Side effects
    1. None of the following side effects have been found dose-related. 
    2. Common side effects (> 1/100, <1/10): headache, stomach pain, diarrhea, bloating, nausea / vomiting, constipation. 
    3. Rare side effects (> 1/1000, <1/100): dermatitis, itching, hives, dizziness, dry mouth. 
    4. The following side effects have been observed in the use of racemaic modification (omeprazole), and therefore they may also occur during the use of esomeprazole.
  • Description Esomeprazole, formulated as a magnesium salt, reached the market as a treatment for acid-related diseases such as gastro-esophageal reflux (GERD) disease including peptic ulcer disease and reflux esophagitis. Esomeprazole (formerly perprazole) is the active (S)- enantiomer of omeprazole (1988) and the first proton pump inhibitor developed as an optical isomer. It can be obtained by several routes such as asymmetric oxidation of the pro-chiral pyridylmethyl benzimidazole sulfide, separation from the racemic sulfoxide by chiral chromatography or separation of a diastereomeric mixture obtained from the racemic compound and a chiral acid, followed by hydrolysis. Biochemical studies have shown that esomeprazole irreversibly inhibits the gastric H+/K+-adenosine triphosphatase (ATPase), an enzyme system involved at the secretory surface of the stomach’s parietal cells responsible for the secretion of gastric acid. Compared with racemic omeprazole in healthy subjects, esomeprazole has higher bioavailability, is absorbed more rapidly and exhibits a more uniform and predictable dose-response with higher plasma levels, leading to less inter-individual variability between slow and rapid metabolizers. In extensive clinical trials in patients suffering from GERD symptoms, esomeprazole provided superior acid control and significantly reduced the healing time compared to omeprazole.
  • Originator AstraZeneca (UK)
  • Definition ChEBI: A 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole that has S configuration at the sulfur atom. An inhibitor of gastric acid secretion, it is used (generally as its sodium or magnesium alt) for the treatment of gastro-oesophageal reflux disease, dyspepsia, peptic ulcer disease, and Zollinger-Ellison syndrome.
  • brand name Nexium
Esomeprazole Preparation Products And Raw materials
Raw materials
Preparation Products
  • Supplier:
    Henan Tianfu Chemical Co.,Ltd.
  • Tel:0371-55170693
  • Fax:0371-55170693
  • Country:CHINA
  • ProdList:22623
  • Advantage:55
  • Supplier:
    career henan chemical co
  • Tel:+86-371-86658258
  • Fax:
  • Country:CHINA
  • ProdList:30032
  • Advantage:58
  • Supplier:
    Zhonglan Industry Co., Ltd.
  • Tel:(86) 531-82956570
  • Fax:(86) 531-82956571
  • Country:CHINA
  • ProdList:4895
  • Advantage:58
  • Supplier:
  • Tel:(323) 306-3136
  • Fax:(626) 453-0409
  • Country:United States
  • ProdList:8406
  • Advantage:58
  • Supplier:
    Chongqing Chemdad Co., Ltd
  • Tel:+86-13650506873
  • Fax:
  • Country:CHINA
  • ProdList:35434
  • Advantage:58
  • Supplier:
    Alchem Pharmtech,Inc.
  • Tel:8485655694
  • Fax:
  • Country:United States
  • ProdList:63728
  • Advantage:58
119141-88-7, EsomeprazoleRelated Search:
  • EsoMeprazole EC Pellets 22%
  • EsoMaprozole
  • 1H-BenziMidazole,6-Methoxy-2-[(S)-[(4-Methoxy-3,5-diMethyl-2-pyridinyl)Methyl]sulfinyl]-
  • 5-Methoxy-2-(4-Methoxy-3,5-diMethyl-pyridin-2-ylMethanesulfinyl)-1H-benzoiMidazole
  • EsoMeprazole EC Pellets 8.5%
  • 6-Methoxy-2-{(S)-[(4-Methoxy-3,5-diMethyl-2-pyridinyl)Methyl]sulfinyl}-1H-benziMidazole
  • Esomeprazole(Na、Mg)
  • (5-methoxy-1H-benzimidazol-2-yl)[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfoniumolate
  • (S)-Esomeprazole
  • Esomeprazole(Mg)
  • 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)-1H-benzimidazole
  • 6-Methoxy-2-[(R)-(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-1H-benzoimidazole
  • Esomeprazole
  • Omeprazole S-Isomer
  • (RelCpd F)
  • (S)-5-Methoxy-2-((4-Methoxy-3,5-diMethylpyridin-2-yl)Methylsulfinyl)-1H-benzo[d]iMidazole
  • (R)-5-Methoxy-2-(((4-Methoxy-3,5-diMethylpyridin-2-yl)Methyl)sulfinyl)-1H-benzo[d]iMidazole
  • 5-Methoxy-2-(((4-Methoxy-3,5-diMethylpyridin-2-yl)Methyl)sulfinyl)-1H-benzo[d]iMidazole
  • 119141-58-6
  • esomeprazole:5-methoxy-2-((s)-((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)-1h-benzIMIDAZOLE
  • Esomeprazol
  • Esomeprazol EP Impurity F
  • (S)-6-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
  • -6-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)
  • Aisi'aomeilazuona Esomeprazole Sodium
  • Esomeprzole
  • 119141-88-7
  • 119141-58-6
  • 217097-09-7
  • API